KYTHERA Biopharmaceuticals, Inc.KYTH announced that it has submitted an investigational new drug application (IND) to the FDA for KYTH 105 (setipiprant selective oral antagonist of the prostaglandin D 2 (PGD 2 ) receptor) for the treatment of androgenetic alopecia
KYTHERA Files IND Application for Male Hair Loss Treatment
